Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei CBA L74
- Development stage
- Unknown
- Lead developer
- Kraft Heinz
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei CBA L74 is a specific probiotic bacterial strain that has been developed in a **heat-killed/postbiotic fermented food formulation**, including fermented rice flour for oral use in infants. In the provided public clinical-publication context, it was studied as an adjunct to topical therapy for **atopic dermatitis** in infants aged 6-36 months. The reported study found no significant improvement in SCORAD versus placebo over 12 weeks, but did observe a **topical steroid-sparing effect**, while gut microbiota composition and serum cytokines were not significantly different between groups. The product is best characterized as a microbiome-related nutritional/postbiotic intervention rather than a conventional pharmaceutical drug; its proposed activity is host immune and barrier modulation through exposure to bacterial components and fermentation-derived metabolites rather than direct engagement of a single defined molecular target.
- Other names
- Lactobacillus paracasei CBA L74heat-killed Lactobacillus paracasei CBA L74fermented rice flour obtained from Lactobacillus paracasei CBA L74
Beyond the preview
Go deeper on Lactobacillus paracasei CBA L74.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei CBA L74.